Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.

Naimi RM, Hvistendahl M, Enevoldsen LH, Madsen JL, Fuglsang S, Poulsen SS, Kissow H, Pedersen J, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Holst JJ, Hartmann B, Hansen SH, Dragsted LO, Steensberg A, Mouritzen U, Hansen MB, Jeppesen PB.

Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363. doi: 10.1016/S2468-1253(19)30077-9. Epub 2019 Mar 15.

PMID:
30880176
2.

Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.

Hövelmann U, Olsen MB, Mouritzen U, Lamers D, Kronshage B, Heise T.

Diabetes Obes Metab. 2019 Mar;21(3):601-610. doi: 10.1111/dom.13562. Epub 2018 Nov 28.

3.

Inhibition of Cx43 gap junction uncoupling prevents high glucose-induced apoptosis and reduces excess cell monolayer permeability in retinal vascular endothelial cells.

Kim D, Mouritzen U, Larsen BD, Roy S.

Exp Eye Res. 2018 Aug;173:85-90. doi: 10.1016/j.exer.2018.05.003. Epub 2018 May 9.

PMID:
29750972
4.

Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial.

Engstrøm T, Nepper-Christensen L, Helqvist S, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamaki K, Tilsted HH, Steensberg A, Fabricius S, Mouritzen U, Vejlstrup N, Ahtarovski KA, Göransson C, Bertelsen L, Kyhl K, Olivecrona G, Kelbæk H, Lassen JF, Køber L, Lønborg J.

Heart. 2018 Oct;104(19):1593-1599. doi: 10.1136/heartjnl-2017-312774. Epub 2018 Mar 30.

PMID:
29602883
5.

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.

Hövelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, Møller DV, Heise T.

Diabetes Care. 2018 Mar;41(3):531-537. doi: 10.2337/dc17-1402. Epub 2017 Dec 22.

PMID:
29273578
6.

Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial.

Ignatenko S, Skrumsager BK, Mouritzen U.

Int J Clin Pharmacol Ther. 2016 Apr;54(4):243-52. doi: 10.5414/CP202474.

PMID:
26833462
7.

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).

Grünwald V, Desar IM, Haanen J, Fiedler W, Mouritzen U, Olsen MW, van Herpen CM.

Acta Oncol. 2011 Jan;50(1):121-6. doi: 10.3109/0284186X.2010.509104.

PMID:
21174612
8.

Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.

Schmidt H, Brown J, Mouritzen U, Selby P, Fode K, Svane IM, Cook GP, Mollerup DH, Geertsen PF.

Clin Cancer Res. 2010 Nov 1;16(21):5312-9. doi: 10.1158/1078-0432.CCR-10-1809. Epub 2010 Oct 19.

9.

Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes.

Parkner T, Dyrskog SE, Laursen T, Chen JW, Mouritzen U, Brondsted L, Hermansen K, Lauritzen T, Christiansen JS.

Diabetes Obes Metab. 2010 May;12(5):414-20. doi: 10.1111/j.1463-1326.2009.01178.x.

PMID:
20415689
10.

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G.

Clin Cancer Res. 2009 Mar 15;15(6):2123-9. doi: 10.1158/1078-0432.CCR-08-2663. Epub 2009 Mar 10.

11.

Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.

Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.

Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):511-9.

PMID:
17115349
12.

Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM).

Christgau S, Tankó LB, Cloos PA, Mouritzen U, Christiansen C, Delaissé JM, Høegh-Andersen P.

Menopause. 2004 Sep-Oct;11(5):508-18.

PMID:
15356403
13.

Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.

Raz I, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Harman-Boehm I.

Clin Ther. 2003 Dec;25(12):3109-23.

PMID:
14749149
14.

Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.

Tankó LB, Mouritzen U, Lehmann HJ, Warming L, Moelgaard A, Christgau S, Qvist P, Baumann M, Wieczorek L, Hoyle N, Christiansen C.

Bone. 2003 Jun;32(6):687-93.

PMID:
12810176
16.

Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.

Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C.

Ann Rheum Dis. 2002 Jun;61(6):530-3.

17.

Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women.

Tankó LB, Movsesyan L, Mouritzen U, Christiansen C, Svendsen OL.

Metabolism. 2002 Jan;51(1):69-74.

PMID:
11782875

Supplemental Content

Loading ...
Support Center